| Dr Nilofer Anwar Kidiwala, DO | |
|
1875 Dempster St Ste 180, Park Ridge, IL 60068-1144 | |
| (844) 725-5238 | |
| (847) 723-2791 |
| Full Name | Dr Nilofer Anwar Kidiwala |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 1875 Dempster St Ste 180, Park Ridge, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295022218 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QH0002X | Family Medicine - Hospice And Palliative Medicine | 036134639 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Lutheran General Hospital | Park ridge, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.
In 2016, the National Institutes of Health implemented a policy which requires grant applicants to "consider sex as a biological variable" in vertebrate animal and human studies. A new study surveyed NIH study section members in 2016 and 2017 regarding their attitudes toward the policy and found that a majority of respondents thought that it was important to consider SABV in the experimental design and that considering SABV would improve the rigor and reproducibility of NIH-funded preclinical research.
Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.
Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.
› Verified 4 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.
In 2016, the National Institutes of Health implemented a policy which requires grant applicants to "consider sex as a biological variable" in vertebrate animal and human studies. A new study surveyed NIH study section members in 2016 and 2017 regarding their attitudes toward the policy and found that a majority of respondents thought that it was important to consider SABV in the experimental design and that considering SABV would improve the rigor and reproducibility of NIH-funded preclinical research.
Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.
Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.
› Verified 4 days ago
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386863819 PECOS PAC ID: 3072422716 Enrollment ID: O20031112000158 |
News Archive
Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.
In 2016, the National Institutes of Health implemented a policy which requires grant applicants to "consider sex as a biological variable" in vertebrate animal and human studies. A new study surveyed NIH study section members in 2016 and 2017 regarding their attitudes toward the policy and found that a majority of respondents thought that it was important to consider SABV in the experimental design and that considering SABV would improve the rigor and reproducibility of NIH-funded preclinical research.
Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.
Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.
› Verified 4 days ago
| Entity Name | Journeycare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154324994 PECOS PAC ID: 2062578305 Enrollment ID: O20090512000566 |
News Archive
Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.
In 2016, the National Institutes of Health implemented a policy which requires grant applicants to "consider sex as a biological variable" in vertebrate animal and human studies. A new study surveyed NIH study section members in 2016 and 2017 regarding their attitudes toward the policy and found that a majority of respondents thought that it was important to consider SABV in the experimental design and that considering SABV would improve the rigor and reproducibility of NIH-funded preclinical research.
Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.
Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nilofer Anwar Kidiwala, DO 29373 Network Pl, Chicago, IL 60673-1293 Ph: (847) 390-5900 | Dr Nilofer Anwar Kidiwala, DO 1875 Dempster St Ste 180, Park Ridge, IL 60068-1144 Ph: (844) 725-5238 |
News Archive
Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.
In 2016, the National Institutes of Health implemented a policy which requires grant applicants to "consider sex as a biological variable" in vertebrate animal and human studies. A new study surveyed NIH study section members in 2016 and 2017 regarding their attitudes toward the policy and found that a majority of respondents thought that it was important to consider SABV in the experimental design and that considering SABV would improve the rigor and reproducibility of NIH-funded preclinical research.
Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.
Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.
› Verified 4 days ago
Dr. John Charles Evans, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 112 S Northwest Hwy, Park Ridge, IL 60068 Phone: 847-696-3370 Fax: 847-696-9445 | |
Dr. Dimitrina Vizinas, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1440 Renaissance Dr Ste 300, Park Ridge, IL 60068 Phone: 847-254-9714 Fax: 847-803-1806 | |
Dr. Agnieszka Kania, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1875 Dempster St, 506, Park Ridge, IL 60068 Phone: 847-593-6600 | |
Dr. Maureen E Grosdidier, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 850 Busse Hwy, Park Ridge, IL 60068 Phone: 847-825-0300 Fax: 847-825-1825 | |
Stuart Lewis Goldman, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1775 Ballard Rd, Park Ridge, IL 60068 Phone: 847-318-6020 Fax: 847-318-2712 | |
Dr. Dorina Feher, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1775 Ballard, Nesset Family Medicine Center, Park Ridge, IL 60068 Phone: 847-318-6020 | |
Dr. Anthony T Mccormack, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1875 Dempster St Ste 520, Park Ridge, IL 60068 Phone: 847-720-6464 Fax: 847-720-6463 |